Strategic Trials to Define the Best Available Treatment for Neonatal and Pediatric Sepsis Caused by Carbapenem-resistant Organisms

Daniele Donà; Mike Sharland; Paul T Heath; Laura Folgori

doi:10.1097/INF.0000000000002381

Strategic Trials to Define the Best Available Treatment for Neonatal and Pediatric Sepsis Caused by Carbapenem-resistant Organisms

Pediatr Infect Dis J. 2019 Aug;38(8):825-827. doi: 10.1097/INF.0000000000002381.

Authors

Daniele Donà^{1

2}, Mike Sharland¹, Paul T Heath¹, Laura Folgori^{1

3}

Affiliations

¹ From the Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George's University of London, London, United Kingdom.
² Division of Paediatric Infectious Diseases, Department for Woman and Child Health, University of Padua, Padua.
³ Paediatric Infectious Disease Unit, Department of Paediatrics, Luigi Sacco Hospital, University of Milan, Milan, Italy.

PMID: 31261359
DOI: 10.1097/INF.0000000000002381

Abstract

The optimal standard of care for carbapenem-resistant bloodstream infections in children is currently unknown. This systematic review, aiming to define the best available treatments to be compared with new antibiotics in clinical trials, clearly points out the paucity of available data. The simplification and a wider harmonization of study design are a global priority to inform the best strategies to treat these life-threatening infections in children.

Publication types

Meta-Analysis

MeSH terms

Adolescent
Age Factors
Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use*
Carbapenems / pharmacology
Carbapenems / therapeutic use*
Child
Child, Preschool
Clinical Trials as Topic
Disease Management
Female
Humans
Infant
Infant, Newborn
Male
Prognosis
Sepsis / diagnosis
Sepsis / drug therapy*
Sepsis / microbiology*
Sepsis / mortality
Treatment Outcome
beta-Lactam Resistance / drug effects*

Substances

Anti-Bacterial Agents
Carbapenems